share_log

Despite Shrinking by CN¥464m in the Past Week, Shenzhen Original Advanced Compounds (SHSE:603991) Shareholders Are Still up 40% Over 5 Years

Despite Shrinking by CN¥464m in the Past Week, Shenzhen Original Advanced Compounds (SHSE:603991) Shareholders Are Still up 40% Over 5 Years

儘管過去一週萎縮了4.64億元人民幣,但深圳原創先進化合物(上海證券交易所代碼:603991)的股東在5年內仍上漲了40%
Simply Wall St ·  03/28 14:02

Shenzhen Original Advanced Compounds Co., Ltd. (SHSE:603991) shareholders might be concerned after seeing the share price drop 28% in the last quarter. But that doesn't change the fact that the returns over the last five years have been pleasing. Its return of 38% has certainly bested the market return!

深圳原創高新化合物有限公司(SHSE: 603991)股東在看到上個季度股價下跌28%後可能會感到擔憂。但這並不能改變過去五年的回報令人愉快的事實。其38%的回報率無疑超過了市場回報率!

While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.

儘管過去一週減損了該公司的五年回報率,但讓我們來看看基礎業務的最新趨勢,看看漲幅是否一致。

Because Shenzhen Original Advanced Compounds made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

由於深圳原創先進化合物在過去十二個月中出現虧損,我們認爲至少目前市場可能更加關注收入和收入增長。當一家公司沒有盈利時,我們通常希望看到良好的收入增長。可以想象,收入的快速增長如果持續下去,通常會帶來利潤的快速增長。

In the last 5 years Shenzhen Original Advanced Compounds saw its revenue shrink by 34% per year. Even though revenue hasn't increased, the stock actually gained 7%, per year, during the same period. It's probably worth checking other factors such as the profitability, to try to understand the share price action. It may not be reflecting the revenue.

在過去的5年中,深圳原創先進化合物的收入每年減少34%。儘管收入沒有增加,但同期該股實際上每年上漲7%。爲了了解股價走勢,可能值得檢查其他因素,例如盈利能力。它可能無法反映收入。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
SHSE:603991 Earnings and Revenue Growth March 28th 2024
SHSE: 603991 2024 年 3 月 28 日收益和收入增長

This free interactive report on Shenzhen Original Advanced Compounds' balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於深圳原創高級化合物資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

While it's never nice to take a loss, Shenzhen Original Advanced Compounds shareholders can take comfort that their trailing twelve month loss of 10% wasn't as bad as the market loss of around 15%. Longer term investors wouldn't be so upset, since they would have made 7%, each year, over five years. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Shenzhen Original Advanced Compounds .

儘管虧損從來都不是一件好事,但深圳原創先進化合物的股東們可以放心,他們過去十二個月的10%虧損沒有15%左右的市場虧損那麼嚴重。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺7%。在最好的情況下,去年只是通往更光明未來之旅中的一個暫時階段。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。爲此,你應該注意我們在深圳原創先進化合物中發現的兩個警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論